Cowen Starts Nautilus Biotechnology (NAUT) at Outperform

Cowen analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ: NAUT) with an Outperform rating.

The analyst commented, "We initiate coverage of NAUT at Outperform, given our view that the risk/reward profile of the stock (at current levels) is calibrated for the company’s technology development (and commercial launch) risks, and the large market opportunity it may serve if/when successful. NAUT remains in early days, but has delivered early evidence of success in its mission to "unlock" the proteome."

For an analyst ratings summary and ratings history on Nautilus Biotechnology click here. For more ratings news on Nautilus Biotechnology click here.

Shares of Nautilus Biotechnology closed at $5.44 yesterday.

You May Also Be Interested In

• TD Cowen Resumes EQT Corp. (EQT) at Hold
• Loop Capital Starts DoorDash Inc. (DASH) at Buy, 'Category Killer with Stellar Execution'
• Alpine Income Property Trust (PINE) PT Lowered to $18 at Jones Trading